Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Previous studies suggest angiotensin receptor blockers (ARBs) may lower epilepsy risk compared to other antihypertensives.
• Observational data from the US specifically examining this association are limited.

Purpose of the Study:

• To evaluate the association between ARB use and epilepsy incidence in US hypertensive patients.
• To compare epilepsy risk among users of ARBs versus other major antihypertensive classes.

Main Methods:

• Retrospective cohort study using a national health administrative database (2010-2017).
• Propensity score matching was employed to compare ARB users with users of angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers (β-blockers), or calcium channel blockers (CCBs).
• Cox regression analyses assessed epilepsy incidence during follow-up.

Main Results:

• The study included over 2.2 million hypertensive patients, with propensity score matching creating comparable subgroups.
• ARB use was associated with a significantly lower incidence of epilepsy compared to ACEIs (aHR, 0.75), β-blockers (aHR, 0.70), and CCBs (aHR, 0.72).
• Subgroup analyses indicated that losartan, a specific ARB, showed a significant association with lower epilepsy incidence, especially in patients without prior stroke or cardiovascular disease.

Conclusions:

• Angiotensin receptor blockers (ARBs), notably losartan, are associated with a reduced incidence of epilepsy in hypertensive patients compared to other antihypertensive agents.
• The findings suggest potential antiepileptogenic properties of ARBs, particularly in individuals without pre-existing cardiovascular conditions.
• Further research, including randomized clinical trials, is recommended to confirm these comparative antiepileptogenic effects.